Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.40 |
| ▸ | SQLE | Q14534 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122720 | 1.00 | KMT2A (0.43) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL123153 | 1.00 | KMT2A (0.43) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL5857338 | 0.99 | KMT2A (0.44) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL121994 | 0.99 | KMT2A (0.41) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL5857342 | 0.99 | KMT2A (0.44) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL121342 | 0.99 | KMT2A (0.41) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL120741 | 0.97 | KMT2A (0.42) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL120742 | 0.97 | KMT2A (0.42) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10706181 | 0.94 | KMT2A (0.46) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL118427 | 0.94 | KMT2A (0.46) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | claimed |
| EP-2424568-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | University Of Kentucky Research Foundation (US) | 2012-03-07 | — | — | EP | claimed |
| US-7879344-B2 | contains antiitch agent; for use in wipes and absorbent articles, and transdermal patches | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2011-02-01 | — | — | US | claimed |
| WO-2010126501-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-04 | — | — | WO | claimed |
| US-20080003273-A1 | Transdermal Delivery of Oleocanthal for Relief of Inflammation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-01-03 | — | — | US | claimed |
| US-12636309-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12636308-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250249031-A1 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | ADORA LIFE SCIENCE, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250249030-A1 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | ADORA LIFE SCIENCE, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12303528-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4537829-A2 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | University Of Manitoba (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20020001567-A1 | Intracorporeal medicaments for high energy phototherapeutic treatment of disease | PHOTOGEN, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001076595-A1 | INTRACORPOREAL MEDICAMENTS FOR HIGH ENERGY PHOTOTHERAPEUTIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001072301-A1 | INTRACORPOREAL MEDICAMENTS FOR PHOTODYNAMIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1137409-A2 | COMPOSITIONS AND METHODS FOR AMELIORATION OF HUMAN FEMALE SEXUAL DYSFUNCTION | Nexmed Holdings, Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
| US-20010022970-A1 | Intracorporeal medicaments for photodynamic treatment of disease | PHOTOGEN, INC. | 2001-09-20 | — | — | US | disclosed |
| WO-2001012181-A1 | IMPROVED TOPICAL MEDICAMENTS AND METHODS FOR PHOTODYNAMIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000033825-A2 | COMPOSITIONS AND METHODS FOR AMELIORATION OF HUMAN FEMALE SEXUAL DYSFUNCTION | NEXMED HOLDINGS, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5879690-A | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers | N.V. PERRICONE LLC | 1999-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003273-A1 | Transdermal Delivery of Oleocanthal for Relief of Inflammation | OXER1, OSBP, OXGR1 | KMT2A 4154/4885MAPT 302/4885MEN1 4874/4885 |
| US-12636308-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | FUT6, CD44, CSGALNACT1 | KMT2A 4373/4885MAPT 1043/4885MEN1 4842/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | KMT2A 2718/4885MAPT 3613/4885MEN1 4840/4885 |
| US-12636309-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | CD44, FUT8, FUT6 | KMT2A 3811/4885MAPT 558/4885MEN1 3690/4885 |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | CNR2, CNR1, FAAH | KMT2A 3922/4885MAPT 1463/4885MEN1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.